Multiple predicted targets – no validated primary molecular target

The designation "Multiple predicted targets – no validated primary molecular target" is a classification used in pharmacological databases to describe compounds for which a specific, primary molecular target has not been definitively identified or validated. This situation is frequently encountered with drugs discovered through phenotypic screening, where the focus is on the physiological outcome rather than a specific protein interaction (Moffat et al., 2017, Nature Reviews Drug Discovery). While computational models may predict various potential binding partners, these interactions often lack the experimental evidence required for validation as a primary therapeutic target. This category encompasses a variety of substances, including legacy medications, complex natural products, and compounds that exhibit significant polypharmacology. In such cases, the clinical efficacy of the drug is often the result of modulating multiple biological pathways simultaneously rather than hitting a single target (ChEMBL Database). The lack of a validated target poses unique challenges for rational drug design and the optimization of chemical structures for better potency or selectivity. Furthermore, it complicates the prediction of off-target toxicities and the development of specific biomarkers for patient selection. Regulatory agencies often approve such drugs based on demonstrated safety and efficacy in clinical trials, even when the precise molecular mechanism remains unknown (FDA, Guidance for Industry). Consequently, these agents represent a target-agnostic approach to therapy that remains a significant area of research in modern drug discovery.

Other names

Unknown targetUnassigned targetNon-specific targetPhenotypic targetTarget-agnostic

The mechanism of action is not linked to a single validated molecular target; therapeutic effects may result from polypharmacology or non-specific interactions.